ANI Pharma (ANIP) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance
May 8, 2018 8:30 AM EDTBAUDETTE, Minn., May 8, 2018 /PRNewswire/ --
For the first quarter 2018:
Net revenues of $46.5 million, an increase of 27% as compared to the same period in 2017 GAAP net income of $2.3 million and diluted GAAP earnings per share of $0.19 Adjusted non-GAAP EBITDA of $21.8 million Adjusted non-GAAP diluted earnings per share of $1.32ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported its financial results for the three months ended March 31, 2018 and reaffirmed its 2018 financial guidance. The Company will host its earnings... More



